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INTRODUCTION
Vaccinia viruses (VV) have been widely used as vaccines1 and as gene 
therapy vectors2 for decades and are thus relatively well characterized 
and bear a solid safety profile.3 Vaccinia virus has also been used as an 
oncolytic agent in many preclinical and clinical studies3–5 thanks to its 
fast replication cycle3 and high tropism to cancer tissues.6
In oncolytic virotherapy, the ability of the virus to activate the 
immune system against tumors is nowadays generally understood 
to be a key mechanism in full eradication of cancer and for  long-term 
antitumor effects.7,8 In fact, the best results so far in VV-based onco-
lytic virotherapy have been achieved by using viruses that express 
immunostimulatory transgenes.4,5,9–11
Vaccinia viruses are immunosuppressive viruses by nature encod-
ing many proteins to evade host immune responses.12 To overcome 
this problem, we developed an oncolytic VV that expresses intra-
cellular pattern recognition receptor DNA-dependent activator of 
 IFN-regulatory factors (DAI) to obtain a self-immuno-boosting sys-
tem to activate immune responses in the tumor.
DAI, also known as ZBP1 (Z-DNA-binding protein 1) or DLM-1 
is a cytosolic dsDNA sensor that is a potent activator of innate 
immune responses.13 Activation of DAI increases the production 
of type I interferons and other cytokines that attract immune cells 
to the site of activation (infection).14 Lladser et al.14 showed that a 
 DAI-expressing plasmid can be efficiently used as a genetic can-
cer vaccine inducing memory and effector tumor-specific T-cells. 
Similarly, myeloid differentiation factor 88 (MyD88), a ubiquitous 
Toll-like receptor adaptor molecule, has been used as a genetic 
adjuvant to harness intrinsic immune-stimulating properties of a 
DNA vaccine15 and a MyD88-encoding adenovirus was shown to 
potentiate local and systemic antitumor immunity.16
Since vaccinia virus is a dsDNA virus whose entire replication cycle 
takes place in the cytosol,12 we hypothesized that DAI has a role in 
innate immune sensing of VV. Moreover, we thought that expres-
sion of DAI by a rapidly replicating viral backbone would boost 
innate immune activation and counteract the immunosuppressive-
ness of the virus12 and the tumor microenvironment,17 resulting in 
long-lasting adaptive immunity towards cancer.
RESULTS
DAI-armed oncolytic vaccinia virus displays unaltered oncolytic 
activity
To improve the immunogenicity of oncolytic vaccinia virus, we gen-
erated a virus expressing DAI. Separate viruses coding for human 
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ally the long-lasting adaptive immunity against cancer.
Molecular Therapy — Oncolytics (2016) 3, 16002; doi:10.1038/mto.2016.2; published online 23 March 2016
1Laboratory of ImmunoViroTherapy, Centre for Drug Research (CDR), Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland; 2Cancer 
Gene Therapy Group, Department of Pathology and Transplantation Laboratory, Haartman Institute, University of Helsinki, Helsinki, Finland; 3Department of Movement Sciences 
and Wellness (DiSMEB), University of Naples Parthenope and CEINGE-Biotecnologie Avanzate, Naples, Italy; 4Oncos Therapeutics Ltd., Helsinki, Finland; 5Institute of Biotechnology, 
University of Helsinki, Helsinki, Finland; 6TILT Biotherapeutics, Ltd., Helsinki, Finland; 7Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland; 8Finnish 
Institute of Occupational Health, Helsinki, Finland. Correspondence: V Cerullo (vincenzo.cerullo@helsinki.fi)
Expression of DAI by an oncolytic vaccinia virus boosts the 
immunogenicity of the virus and enhances antitumor immunity
Mari Hirvinen1, Cristian Capasso1, Kilian Guse2, Mariangela Garofalo1, Andrea Vitale3, Marko Ahonen2, Lukasz Kuryk1,4,  
Markus Vähä-Koskela5, Akseli Hemminki2,6,7, Vittorio Fortino8, Dario Greco8 and Vincenzo Cerullo1
ARTICLE
2
Oncolytic vaccinia virus expressing DAI
M Hirvinen et al.
Molecular Therapy — Oncolytics (2016) 16002 Official journal of the American Society of Gene & Cell Therapy
(vvdd-tdTomato-hDAI) and mouse DAI (vvdd-tdTomato-mDAI) 
were constructed (Figure 1a). We used a Western Reserve vaccinia 
virus strain with two deletions, one in the thymidine kinase gene and 
another in the vaccinia growth factor  gene.9,18,19 These gene dele-
tions render the virus cancer-specific since their expression is nec-
essary for replication in normal cells but not in cancer cells where 
the corresponding pathways are already active.20,21 Both versions 
of DAI-expressing viruses and the control virus  vvdd-tdTomato 
express a tdTomato fluorophore for in vitro and in vivo imaging pur-
poses and biosafety concerns.9,22
vvdd-tdTomato-hDAI, vvdd-tdTomato-mDAI, and their relative 
controls were tested for cancer cell killing potency in several tumor 
cell lines. The expression of DAI was shown not to hinder cancer cell 
killing efficacy compared to the control virus without the transgene 
in all tested cell lines (Figure 1b).
Infection with a DAI-armed virus promotes expression of genes 
involved in activation of the immune system
Next we wanted to study the overall impact of the DAI-expressing 
virus on the transcriptome of cancer cells and immune cells. To this 
end, we performed a wide-genome expression profile for two dif-
ferent cell types, human melanoma cells (HS294T), and human 
monocyte cells (THP-1) that were infected with the hDAI-virus or a 
control virus that does not express DAI.
Differentially expressed genes were plotted in a two-dimensional 
chart to assess the rigorousness of our analysis; this representation 
shows the consistency of the effects promoted by DAI-armed virus 
in the different cell lines (Supplementary Figure S1). Then we used 
the BACA representing tools23 to concisely report the biological pro-
cesses associated with the significantly downregulated and upregu-
lated genes. The BACA plot analysis revealed a similar effect of the 
Figure 1  Characteristics of the double deleted oncolytic vaccinia virus expressing DAI. (a) Schematic figures of the virus constructs. Two novel armed 
vaccinia viruses were generated expressing human (vvdd-tdTomato-hDAI) or murine DAI (vvdd-tdTomato-mDAI). Both viruses express also tdTomato 
fluorescent protein as a reporter gene and are deleted in thymidine kinase and vaccinia growth factor genes. (b) DAI-expression does not hinder virus 
replication and cell killing efficacy. MTS cell viability assays were performed in several cell lines 5 days postinfection. Virus expressing human DAI was 
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viruses in the melanoma cell line HS294T but a very different one in 
the monocyte cell line THP-1 (Figure 2). This indicates that DAI-VV 
can have a very different effect depending on the nature of the cell 
line. In the THP-1 cell line, there were a lot more upregulated genes 
than in the melanoma cell line. To deepen our understanding on 
what those differently expressed genes were and what is the effect 
that the DAI-armed virus has on the immunological processes, we 
performed ingenuity pathway analysis on differentially expressed 
genes between vvdd-tdTomato-hDAI and vvdd-tdTomato in THP-1 
cells. Interestingly, the most upregulated networks encompassed 
pathways related to immune system activation such as dendritic cell 
maturation, communication between innate and adaptive immune 
systems, and role of pattern recognition receptors in recognition of 
viruses (Supplementary Figure S2).
As expected, we also found about sevenfold upregulation of DAI 
in both cell lines (7.4 and 7.2 in THP1 and HS294T, respectively) 
treated with DAI-expressing virus compared with the unarmed VV.
In conclusion, we showed that infection with  vvdd-tdTomato-hDAI 
virus promotes upregulation of several genes in monocyte cells and 
those genes are involved in important immunological pathways.
DAI expression by oncolytic vaccinia virus enhances cancer 
eradication in vivo by inducing antitumor T-cell responses in a 
syngeneic melanoma mouse model
The immunogenic potency of the DAI-virus was tested in vivo using 
an aggressive syngeneic melanoma model. Subcutaneous B16-OVA 
tumors were grown in C57BL/6 mice (12 mice/group, one tumor/
mouse). The mice were treated intratumorally on days 0 and 2. We 
observed that tumor growth was significantly (P < 0.001) reduced 
in the group of mice treated with vvdd-tdTomato-mDAI when com-
pared to the group treated with vvdd-tdTomato (Figure 3a), and in 
fact most of the tumors treated with the DAI-virus were completely 
cured. Four mice per group were euthanized on day 12 after the 
first virus treatments and tumors were collected and prepared for 
flow cytometric analysis of immune cells. We found that enhanced 
cancer-eradicating efficacy of the vvdd-tdTomato-mDAI was asso-
ciated with increased (nonsignificant) infiltration of CD8+, CD4+ 
(Figure  3b) and more importantly tumor-specific (OVA-specific) 
CD8+ T-cells into the tumors (Figure 3c).
To further study the role of antitumor immunity induced by 
 vvdd-tdTomato-mDAI treatments, we performed a rechallenging 
experiment using the same mouse melanoma cell line, B16. Ten days 
after the first treatment with viruses, four mice per group received 
another injection of tumor cells from the same (B16-OVA) or differ-
ent cell line without ovalbumin expression (B16-F10) (Figure  4a). 
This allowed assessment whether the immune response was only 
directed to OVA or also towards other tumor-specific antigens. The 
second tumor was not treated, only tumor growth was followed over 
time. The mice that had been treated with vvdd-tdTomato-mDAI 
virus completely rejected the growth of the second B16-OVA tumor 
(Figure 4b), whereas the nontreated mice and the mice treated with 
the control virus did not. All mice treated with the vvdd-tdTomato 
control virus or phosphate-buffered saline (PBS), which received 
injection of  non-OVA-expressing tumor cells, allowed growth of a 
second tumor. In contrast, only half of the mice treated with vvdd-
tdTomato-mDAI grew a B16-F10 tumor (Figure 4c).
At the end of the experiment, 22 days after the first virus treat-
ments and 10 days after tumor cell challenge, the spleens of the 
mice were collected and antitumor and antiviral T-cells were ana-
lyzed with ELISpot (Figure  4d and Supplementary Figure S3). 
Interestingly, the anti-viral T-cell responses were relatively similar 
in both vvdd-tdTomato and vvdd-tdTomato-mDAI treated mice, 
but the antitumor responses were increased in DAI-virus-treated 
mice (no statistical significance, though), especially when the mice 
were rechallenged with exactly the same tumor cell line, B16-
OVA. Intriguingly, we did not only see T-cell responses against the 
Figure 2 Infection of THP-1 monocytes with DAI-armed vaccinia virus 
results in altered expression pattern of genes involved in biological 
processes. HS294T melanoma cells and THP-1 monocytes were infected 
with vvdd-tdTomato-hDAI, vvdd-tdTomato, or phosphate-buffered 
saline, and the wide genome gene expression profile was analyzed. A 
BACA clustering representation of the differentially expressed biological 
processes induced by  vvdd-tdTomato and vvdd-tdTomato-hDAI is shown 
in the two different cell lines. The upregulated genes are marked with red 
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immunogenic OVA peptide, but also against more clinically relevant 
melanoma antigens TRP-2 and gp100.
These findings indicate that vvdd-tdTomato-mDAI is able to 
induce a tumor-specific immune response.
vvdd-tdTomato-hDAI controls growth of human tumors in 
humanized mice and increases infiltration of human immune cells 
into tumors
To even better illustrate the immunogenicity and to demonstrate the 
translational potency of our virus, we performed studies in human-
ized mice bearing human tumors and a human immune system. 
Treatments with vvdd-tdTomato-hDAI resulted in significant con-
trol of tumor growth (P < 0.001) compared to treatments with the 
control virus in presence of the human immune system (Figure 5a). 
Interestingly, the enhanced antitumor effect of the  DAI-virus was 
seen only in mice that received human peripheral blood mono-
nuclear cells (PBMCs), while the effect was absent in mice without 
white blood cells (Figure  5b), which indicates the important role 
of immune system activation as a  mechanism-of-action of the 
DAI-virus.
After the experiment tumors, spleens and blood of the mice 
were collected for flow cytometry analyses. We showed a signifi-
cant (P < 0.01) increase in the number of human CD8+ T-cells in the 
tumors of DAI-virus-treated mice compared to mice treated with the 
control virus (Figure 6a). There was a trend (not significant) toward 
an increased amount of CD8+ and CD4+ T-cells also in the spleens 
and blood of DAI-virus-treated mice (Figure 6b,c).
DISCUSSION
The most promising attempts at oncolytic virotherapy have 
encompassed use of viruses expressing cytokines or other immu-
nostimulatory molecules to turn on the immune system against 
the tumor.24,25 However, the efficacy of the viruses to boost the 
immune system and to elicit a tumor-specific immune response 
Figure 3 In vivo efficacy and antitumor immunity elicited after vvdd-tdTomato-mDAI treatment in an immunocompetent syngeneic melanoma model. 
B16-OVA melanoma tumors were established by injecting 1 × 105 B16-OVA cells subcutaneously into other flank of C57BL/6J mice (N = 12 per group). 
Established tumors (one tumor per mouse, ~4 × 4 mm in diameter) were injected intratumorally with viruses in volume of 50 μl on day 0 with 3 × 106 
pfu/tumor and on day 2 with 1 × 106 pfu/tumor. Mock tumors were injected with phosphate-buffered saline only. (a) Tumor growth was measured over 
time (day 0 = day when the first virus treatment was given). (b) General CD8+ and CD4+ T-cells and (c) tumor-specific (OVA peptide-specific) CD8+ 
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remains modest in preclinical models and cancer patients.24,26 
This may be due to the use of only one single immunostimula-
tory molecule, which may in some cases have limited targets in 
the tumor site due to downregulation of many receptors.16 By 
stimulation of a receptor that regulates and induces production of 
a number of different immunostimulatory cytokines and chemo-
kines would generate a more robust immunological response.12,14 
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a cytosolic sensor for DNA that can induce robust innate immune 
responses once activated. Few years later, Lladser and colleagues 
showed DAI to be an efficient genetic adjuvant for DNA vaccines, 
which can also induce antitumor T-cell responses.14 These intrigu-
ing results encouraged us to use DAI in order to potentiate the 
vaccine effect of an oncolytic vaccinia virus. Therefore, we gener-
ated a novel oncolytic vaccine for cancer immunovirotherapy; our 
approach uses an oncolytic vaccinia virus platform that rapidly 
replicates specifically in tumor cells and expresses DAI at the infec-
tion site. Since the virus is expressing a receptor that senses itself 
(VV DNA), we have generated a self-amplifying system that can 
boost viral immunogenicity and innate immune responses at the 
tumor site regardless of cellular expression of DAI.
In this report, we demonstrate that the oncolytic potency of 
our new virus construct is not hindered compared to an onco-
lytic VV control and thus serves as a rapid and effective platform 
for the immunoboosting molecule DAI. We observed that our 
 DAI-expressing oncolytic VV can activate many relevant path-
ways including those belonging to dendritic cell maturation and 
signaling between innate and adaptive immune systems. This is 
intriguing, since it has been shown by us and others that virus-
induced oncolysis releases tumor antigens to the microenviron-
ment for detection by dendritic cells, which eventually can result 
in activation and maturation of adaptive, tumor-specific immu-
nity.27,28 We showed in this study that the DAI-armed vaccinia virus 
is able to induce T-cell infiltration into treated melanoma tumors 
of C57BL/6 mice accompanied with significantly reduced tumor 
growth. Similarly, activation of the adaptive immune system and 
antitumor responses were also shown by Lladser et  al.14 with a 
DAI-encoding plasmid. In their approach, they used a coadmin-
istration of plasmid expressing tumor antigens to stimulate an 
antigen-specific response. In our case, probably because oncolysis 
is able to release epitopes from tumor cells, and the virus platform 
is more immunogenic, we observed antigen-specific immune 
responses without the need of additional administration of the 
antigen. Our rechallenging experiments also showed that we were 
able to obtain a systemic antitumor response that could control 
the growth of distant nontreated tumors.
It is known that as cancer progresses, it develops several mech-
anisms to evade the host immune system.17,29,30 These tumor 
immune escape mechanisms constitute the immunosuppressive 
tumor microenvironment that creates challenges for immunother-
apies. Likewise, vaccinia viruses have evolved to resist clearance 
by encoding many genes dedicated to protection of the virus from 
the host immune system.12 Our results together with other stud-
ies done with DAI14 demonstrate that by using DAI as an adjuvant, 
we are actually able to convert the tumor microenvironment from 
immunosuppressive into a more favorable variant compatible 
with antitumor immune responses. In fact, we showed that anti-
tumor T-cell responses are more prominent than antiviral T-cell 
responses. Importantly, boosting recognition of viral DNA by the 
expression of DAI, we can also overcome the natural immune eva-
sion mechanisms of the vaccinia virus. This is an intriguing finding 
because Harrington et al.31 have shown that anti-VV responses are 
remarkably stronger than the responses against other epitopes in 
vaccinated mice.
In conclusion, our results suggest that a DAI-armed vaccinia virus 
as a self-sensing and immuno-boosting system can alter the immu-
nosuppressive tumor microenvironment and would be a way to 
improve oncolytic and other vaccination strategies.
MATERIALS AND METHODS
Cell lines
Human lung cancer cell line A549 (ATCC no. CCL-185), human melanoma 
cell lines HS294T (ATCC no. HTB-140), A2058 (ATCC no. CRL-11147), SK-MEL-2 
(ATCC no. HTB-68), human monocyte cell line THP-1 (ATCC no. TIB-202), mon-
key kidney cell line CV-1 (ATCC no. CCL-70), and mouse melanoma cell line 
B16-F10 (ATCC no. CRL-6475) were obtained from the American Type Culture 
Collection (ATCC, Manassas, VA). A highly metastatic human prostate cancer 
cell line PC-3MM2 was generously obtained from Isaiah J. Fidler, MD Anderson 
Cancer Center (Houston, TX). The human bladder cancer EJ cells were provided 
and authenticated by A.G. Eliopoulos, University of Crete Medical School and 
Laboratory of Cancer Biology (Heraklion, Crete, Greece). B16-OVA, a mouse 
melanoma cell line expressing chicken ovalbumin, was kindly provided by 
Professor Richard Vile at Mayo Clinic (Rochester, MN). Jurkat cells, immor-
talized human T-lymphocytes, were kindly provided by Dr. Pentti Tienari, 
Program of Molecular Neurology, University of Helsinki (Helsinki, Finland). All 
cell lines were cultured under recommended conditions.
Figure 4 DAI-virus boosts tumor-specific immunity without boosting anti-viral immunity in mice bearing syngeneic melanoma tumors. (a) Schematic 
of the experiment; B16-OVA melanoma tumors were established by injecting 1 × 105 B16-OVA cells subcutaneously into other flank of C57BL/6J mice 
(N = 12 per group). Established tumors (one tumor per mouse, ~4 × 4 mm in diameter) were injected intratumorally with viruses in volume of 50 μl on 
day 0 with 3 × 106 pfu/tumor and on day 2 with 1 × 106 pfu/tumor. Mock tumors were injected with phosphate-buffered saline only. The mice were 
re-challenged with another tumor of the same background: the mice received either B16-OVA cells or B16-F10 cells 3 × 105 cells/tumor, 10 days after 
the first virus treatment. The second tumor was not treated, only tumor growth was followed. (b) Four mice per group were rechallenged with the same 
tumor cell line (B16-OVA) and (c) four mice per group were rechallenged with a cell line with the same origin but which does not express ovalbumin 
(B16-F10). The mean tumor growth (above) and the growth of individual tumors (below) are presented after the second tumor implantation (day 0 = day 
when second tumor was injected). IFN-γ producing T-cells were assessed from spleens 22 days after virus treatments by ELISpot. Splenocytes were 
cultured with  tumor-associated or virus-associated peptides for 36 hours and spots were counted. (d) Cumulative spot counts of the ELISpot wells of 
B16-OVA rechallenged mice (left) and B16-F10 rechallenged mice (right).
gp100 peptide
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Figure 5 In vivo efficacy and immunogenicity of the DAI-virus in a peripheral blood mononuclear cell (PBMC) humanized melanoma mouse model. 
Human melanoma HS294T cells were injected subcutaneously into both flanks of the NSG mice, 5 × 106 cells/flank. When tumors reached injectable size, 
human PBMCs were injected intravenously to the tail vein in 200 μl of phosphate-buffered saline, 2 × 107 cells/ mouse. Two days later virus treatments 
were started. Tumors were treated on days 0 and 6 with 1 × 106 pfu/ tumor in volume of 50 μl, mock mice were treated with phosphate-buffered saline 
only. Parts of the mice were left without PBMCs to have a study control lacking the immune system. (a) Growth of human melanoma HS294T tumors 
in PBMC humanized NSG mice after virus treatments on days 0 and 6 (N of tumors/group=8). Day 0 = day when the first virus treatment was given. (b) 
Comparison of the tumor growth in mice humanized with PBMCs (N of tumors/group = 8) and mice that did not receive PBMCs (N of tumors/group = 4).
a b
Figure 6 Oncolytic vaccinia virus expressing human DAI induces infiltration of human T-cells into infected human melanoma tumors in  PBMC-
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Viruses
Oncolytic Western Reserve strain vaccinia virus selective for epidermal 
growth factor receptor pathway mutations (vaccinia growth factor) and 
tumor-associated hypermetabolism (thymidine kinase) was armed with 
either human or murine DAI and a tdTomato fluorophore. The control virus 
vvdd-tdTomato has been described elsewhere.32 For generation of the 
 vvdd-tdTomato-mDAI and vvdd-tdTomato-hDAI, the mDAI and hDAI cDNA 
was inserted under the control of the pE/L promoter of pSC65-tdTomato32,33 
to create pSC65-tdTomato-mDAI and pSC65-tdTomato-hDAI. These shuttle 
plasmids were cotransfected with vvdd-luc in CV-1 cells. The viruses were 
propagated on A549 cells and purified by general method described in refs. 
18,34. The infectious viral particle concentration was determined by standard 
crystal violet staining assay on A549 cells.
In vitro tumor cell killing assay
Tumor cells were seeded at 1.0 × 104 cells per well on 96-well plates. On the 
next day cells were infected for 1 hour at 37 °C in 2% FCS containing medium 
and then incubated in 5% medium for 5 days. Cell viability was determined 
by MTS according to the manufacturer’s protocol (Cell Titer 96 AQueous One 
Solution Cell Proliferation Assay; Promega, Nacka, Sweden).
Whole-genome gene expression profiling
Human HS294T and THP-1 cells were treated with vvdd-tdTomato-hDAI, 
vvdd-tdTomato, or PBS as a noninfected control. Total RNA was purified from 
tumor cells after infection with 0.1 pfu/cell of virus for 16 hours. RNeasy Plus 
Mini kit (Qiagen, Venlo, NL) was used according to manufacturer’s instruc-
tions. Independent pools of two RNA samples each (total of 600 ng) were 
labeled using T7 RNA polymerase amplification method (Low Input Quick 
Amp Labeling Kit, Agilent Technologies, Santa Clara, CA), according to 
the instructions of the manufacturer. cRNAs were then labeled with Cy3 
and Cy5 dyes (Agilent Technologies) and hybridized to the Agilent 2-color 
60-mer oligo arrays (Agilent SurePrint G3 Human GE 8x60K). The slides were 
washed and scanned with Agilent Microarray Scanner G2505C (Agilent 
Technologies) and the raw intensity values were obtained with the Feature 
Extraction software, version 11.0.1.1 (Agilent Technologies). Raw data was 
quality checked according to the Agilent standard procedures. Data pro-
cessing and analysis of differential gene expression were done in R. First, 
the probe profile expression data were normalized using quantile normal-
ization and corrected for batch processing effects using ComBat. Next, after 
mapping from probsets to Ensemble gene IDs, the differentially expressed 
genes (DE genes) between pre- and post-treatment samples were identified 
using limma. For the analysis using the limma package, genes were defined 
as being differentially expressed after satisfying a minimum fold-change of 
±1.5 and a maximum Benjamini-Hochberg adjusted P value of 0.01. Finally, 
functional categorization of DE genes was performed using a novel R-based 
package namely BACA. It queries the DAVID knowledgebase and builds a 
chart showing multiple enrichment analysis results across different con-
ditions/treatments. Each annotation in the chart is represented as a circle 
(or bubble) that has a size, indicating how many genes in a list of DE genes 
are associated with it, and a color indicating whether the genes are down- 
(default color is green) or up- (default color is red) regulated.
Animal experiments
All animal experiments were reviewed and approved by the Experimental 
Animal Committee of the University of Helsinki and the Provincial 
Government of Southern Finland. Health status of the mice was frequently 
monitored and as soon as signs of pain or distress were evident they were 
euthanized.
For the study of the syngeneic melanoma model, mice were obtained 
from Harlan Laboratories (Indianapolis, IN) at 8 weeks of age and quar-
antined for 2 weeks before the study. B16-OVA melanoma tumors were 
established by injecting 1 × 105 B16-OVA cells subcutaneously into other 
flank of  10-week-old female C57BL/6J mice (N = 12 per group). Established 
tumors (one tumor per mouse, ~4 × 4 mm in diameter) were injected intra-
tumorally with viruses in volume of 50 μl on day 0 with 3 × 106 pfu/tumor 
and on day 2 with 1 × 106 pfu/tumor. Mock tumors were injected with PBS 
only. In the rechallenging experiment, mice received another tumor, either 
 B16-OVA cells or B16-F10 cells 3 × 105 cells/tumor, 10 days after the first virus 
treatment.
For the study with PBMC humanized mice, the highly immunodeficient 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were received from The Jackson 
Laboratory (Bar Harbor, ME) at 7 weeks of age and quarantined for 3 weeks 
before the study. Human melanoma HS294T cells were injected subcuta-
neously into both flanks of the NSG mice, 5 × 106 cells/ flank. When tumors 
reached injectable size, human PBMCs were injected intravenously to the 
tail vein in 200 μl of PBS, 2 × 107 cells/ mouse (protocol modified from35). Two 
days later virus treatments were started. Tumors were treated on days 0 and 
6 with 1 × 106 pfu/ tumor in volume of 50 μl; mock mice were treated with 
PBS only. Parts of the mice were left without PBMCs to have a study control 
lacking the immune system.
The formula (length × (width)2 × 0.5) was used to calculate the tumor vol-
umes. Mice were euthanized when a tumor reached an average diameter 
of 15 mm.
Isolation of PBMCs for the humanized mice experiment
Human PBMCs were isolated from a buffy coat received from Finnish Red 
Cross Blood service. Buffy coat blood was diluted 1:1 with PBS and PBMCs 
were isolated by Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK) gradi-
ent centrifugation according to manufacturer´s instructions.
HLA typing of tumor cell lines and PBMCs
Genomic DNA was extracted from the HS294T tumor cell line and human 
PBMCs for HLA typing. Qiagen DNeasy blood and tissue kit (Qiagen, Venlo, 
NL) was used to extract DNA by manufacturer´s instructions and the HLA 
genotyping and analysis was carried out in an EFI (European Federation for 
Immunogenetics) accredited HLA Laboratory. The genotyping of HLA-A, -B, 
and -C genes were performed using sequence specific primers (Olerup SSP 
HLA-A-B-C Combi Tray, Applied Biosciences, Stockholm, SE). The reactions 
were performed according to manufacturers’ instructions giving at least four-
digit resolution (for example, HLA-A*01:01). PCR reactions from  agarose-gel 
were evaluated manually and the alleles were called with SCORE software. 
The HLA alleles were assessed using HLA nomenclature release 3.5.0 (IMGT/
HLA database) and carefully interpreted by two persons.
Immune cell analysis
Tumors, spleens, and lymph nodes of treated mice were collected, 
smashed through a 70 μm cell strainer and cultured over night in 
10% RPMI-1640 medium. Single cell suspensions were stained with 
 fluorochrome-conjugated monoclonal antibodies and analyzed using 
a FACSAria flow cytometer (BD Biosciences) or Gallios flow cytometer 
(Beckman Coulter, Brea, CA) and FlowJo 7.6 software (TreeStar, Ashland, 
OR). Anti-mouse FITC-conjugated CD8 (Proimmune), PE-Cy7-conjugated 
CD19 (BioLegend), APC-conjugated CD4 (BioLegend), PE-Cy7-conjugated 
CD3e (BioLegend), PE-conjugated IFNgamma (BioLegend) and APC-
conjugated SIINFEKL MHC-I pentamer (Proimmune, Oxford, UK) were used 
for immunocompetent mouse experiment. Anti-human FITC-conjugated 
CD45RA (BioLegend), PE-conjugated CD197 (BioLegend), PerCP-conjugated 
CD8 (BioLegend),  PE-TexasRed-conjugated CD4 (LifeTechnologies), 
 FITC-conjugated IFNgamma (BioLegend), PE-conjugated IL-6 (BioLegend), 
and APC-conjugated TNFα (BioLegend) were used for humanized mouse 
experiment.
IFN-γ ELISpot assays
The amount of activated, interferon-γ-producing T-cells was studied from 
spleens of treated mice using a Mouse IFN-γ ELISpotPLUS (ALP) kit (Mabtech, 
3321-4APT) according to manufacturer´s instructions. Splenocytes were 
pulsed with PepMix VACV (vaccinia virus) peptide pool (MVA093L, JPT), oval-
bumin peptide SIINFEKL (P93, Proimmune), gp100 peptide KVPRNQDWL 
(P1333, Proimmune) or TRP-2 peptide SVYDFFVWL (P185, Proimmune) in 
concentration of 50 ng/well. Concanavalin A (Sigma Aldrich) was used as 
positive control (500 ng/well). ELISpot plates were read and evaluated by 
ZellNet Consulting (Fort Lee, NJ).
Statistical analysis
Statistical significance was determined by unpaired, two-tailed Student’s 
t-test using GraphPad Prism 6 (GraphPad Software, La Jolla, CA). Differences 
in tumor growth were analyzed using two-tailed Student’s t-test (for immu-
nocompetent mouse experiments) or with the nonparametric Mann–
Whitney test (for immunocompromised mouse experiments). Results are 
presented as mean ± SD or as mean ± SEM for tumor growth. All P values 
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were two-sided and considered statistically significant when P  ≤  0.05 (*), 
P < 0.01 (**), P < 0.001 (***), P < 0.0001 (****).
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